Skip to main content
. 2023 Jul 10;14:1173728. doi: 10.3389/fimmu.2023.1173728

Figure 5.

Figure 5

Effect of Lipo-anti-PD-L1-P4 on tumor growth in tumor-bearing humanized NOG-hIL-4-Tgmice. (A) Protocol for establishing the NOG-hIL-4-Tg mouse model. PD-L1 expression in MDA-MB-231 cells was analyzed using flow cytometry. (B) Kinetics of tumor growth in NOG-hIL-4-Tg mice. Tumor growth was measured from PBMC transplantation (Day 0). The mean volume ± standard error was calculated for each week. After four weeks, the mice were sacrificed. **P < 0.01 (one-way analysis of variance or Student’s t-test) (PBS [n = 11], ATZ [n = 9], Lipo-P4 [n = 7], Lipo-Emp [n = 3]). (C) Representative immunohistochemistry of CD3 expression in tumor tissues. Indicated bars in the tissue sections represent 100 μm. (D) Representative cytokine production patterns of CD3 T cells purified from NOG-hIL-4-Tg mouse spleens and stimulated with CD3/CD28. ATZ, atezolizumab; FCM, flow cytometry; FCS, fetal calf serum; IHC, immunohistochemistry; Lipo-anti-PD-L1-P4 (Lipo-P4), liposome-encapsulated anti-programmed death ligand 1 antibody-conjugated P4; Lipo-Emp, empty liposomes; MFI, mean fluorescence intensity; PBMC, peripheral blood mononuclear cell; PD-L1, programmed death ligand 1.